CHDI OHDSI – ATLAS

DEMONSTRATION OF FOUNDATIONAL CONCEPTS





Overview of Demonstration

- 1. Quick overview of OMOP & Atlas
- 2. What is a Cohort?
- 3. Review of our Research Question
- 4. Guided Demonstrations
 - A. Construct our cohort
 - Build concept set
 - Use concept set to construct cohort
 - B. Feature Analysis
 - C. Treatment Pathways
 - D. Incidence Analysis



OMOP Common Data Model & Atlas





High Level OHDSI Concepts

Clinical Characterization: Who are they? What happened to them? Observation

Patient-level Prediction:

What will happen to them?

Prediction

Population-level Effect Estimation:

What is causing it?

Causal Inference

Montefiore





How Standard Vocabularies Work

Common Use Case for Patient Queries:

• Ever received Drug A

Source	Description	ID	Code Type
Epic	Acetaminophen 325 mg	101	Internal
Allscripts	Tylenol 325 mg	209387	RxNorm
Meditech	Acet – 325 mg	50580049660	NDC

Co	Column visibility Copy CSV Show 15 entries Showing 1 to 15 of 21.871 entries Previous 1 2 3 4 5 145?					5 1459 N		
Ħ	Id 🔶	Code 🔶	Name 🎄	Class 🔶	RC	DRC	Domain 🔶	Vocabulary
1	1125315	161	Acetaminophen	Ingredient	1,332,360	1,332,360	Drug	RxNorm
	43187714	OMOP507213	0.52 ML Acetaminophen 160 MG/ML Oral Powder	Quant Clinical Drug	0	0	Drug	RxNorm Extension







Building Block's of Analysis in Atlas

Concept Sets	 Used to group concepts (cardiovascular disease, Antibiotics) Can create multiple groups (comorbidity)
Cohorts	 Population that meet a definition or have a phenotype All analysis is based on cohorts
Characterizations	 Top-level summary statistics used to describe the cohort Can compare baseline characteristics across cohorts
Pathways	 Describes the sequence of interventions patients received for a duration of time, within a cohort
Incidence Rates	 Measures the occurrence rate of an outcome or event in a cohort for a time at risk





Initial Questions to Ask Before Building a Cohort

- 1. What initial event defines the patient's entry into cohort
- 2. What inclusion criteria are additionally considered to the patient's entry into the cohort?
- 3. What defines a patient's exit from a cohort?





DOING MORE

Cohorts in Atlas

Evaluate list of patients who have a BMI > 30, who developed HTN 6 months after diagnosis of Diabetes.



Demonstration Context: COVID-19

Explain important aspects of pandemic

- Who are the patients?
- What do we know about their baseline characteristics?
 - Age
 - Ethnicity
 - Comorbidities
 - Clinical experiences
- Are there any differences between different communities of COVID-19 patients in terms of their baseline characteristics?
 - Ex. Females vs. Males
 - Ex. Race / Ethnicity
 - Ex. Patients with comorbidities vs. without comorbidities
 - Ex. Treatment A vs. Treatment B
- What were the treatment pathways for patients at our institution
- What is the incidence rate of certain outcomes in different COVID-19 subpopulations



Atlas Graphical User Interface







For Additional Information



- OMOP Data Model
- Introductory Atlas Tutorials
- The Book of OHDSI



Montefiore DOING MORESM



Albert Einstein College of Medicine